M. Nierman

发表

Enhanced apoB48 metabolism in lipoprotein lipase X447 homozygotes.

J. Kastelein, E. Stroes, J. Kuivenhoven, 2007, Atherosclerosis.

Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial

Rutger M van den Bor, F. Rutten, A. Hoes, 2019, BMJ Open.

Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia Published, JLR Papers in Press, July 21, 2006.

P. Talmud, R. Chamuleau, S. Vaessen, 2006, Journal of Lipid Research.

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

A. Zwinderman, M. Hayden, E. Aronica, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?

M. Kruip, S. Cannegieter, F. V. D. van der Meer, 2021, Journal of thrombosis and haemostasis : JTH.

Gene therapy for lipoprotein lipase deficiency: working toward clinical application.

M. Hayden, P. Dijkhuizen, J. Kastelein, 2005, Human gene therapy.

Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.

J. Twisk, J. Kastelein, E. Stroes, 2005, The Netherlands journal of medicine.

Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance.

J. Kastelein, E. Stroes, D. V. van Raalte, 2005, Metabolism: clinical and experimental.

Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study

N. Day, R. Luben, N. Wareham, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia

E. Groot, A. Marais, J. Firth, 2006, Acta paediatrica.

Enhanced Conversion of Triglyceride-Rich Lipoproteins and Increased Low-Density Lipoprotein Removal in LPLS447X Carriers

J. Kastelein, E. Stroes, J. Kuivenhoven, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Lipoprotein lipase gene analyses in one Turkish family and three different Chinese families with severe hypertriglyceridaemia: One novel and several established mutations

J. Defesche, M. Nierman, J. Peter, 2006, Journal of Inherited Metabolic Disease.

New Risk Factors for Atherosclerosis and Patient Risk Assessment

J. Kastelein, E. Stroes, J. Fruchart, 2004, Circulation.

Finding very high lipoprotein(a): the need for routine assessment.

E. Stroes, P. Knaapen, Y. Kaiser, 2021, European journal of preventive cardiology.

7 lipoprotein lipase Gene polymorphisms and the risk of tarGet vessel revascularization after percutaneous coronary intervention

A. Zwinderman, R. J. Winter, J. Kastelein, 2006 .

Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.

A. Zwinderman, R. D. de Winter, J. Kastelein, 2005, Journal of the American College of Cardiology.

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study

M. Huisman, S. Cannegieter, F. V. D. van der Meer, 2021, Journal of thrombosis and haemostasis : JTH.

Working towards personalized anticoagulation management.

M. Nierman, 2022, International journal of cardiology.

Lipoprotein lipase S447X : from benefical gene variant to gene therapy

M. Nierman, 2006 .

Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation

M. Hayden, J. Jukema, J. Kastelein, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding

N. Delsaux, P. Talmud, J. Kastelein, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns

M. Huisman, S. Cannegieter, W. Lijfering, 2020, Journal of thrombosis and haemostasis : JTH.

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis

S. Cannegieter, F. V. D. van der Meer, W. Lijfering, 2021, Research and Practice in Thrombosis and Haemostasis.

Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk.

M. Sprangers, J. Kastelein, E. Stroes, 2012, The American journal of cardiology.

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants

M. Huisman, S. Cannegieter, F. V. D. van der Meer, 2020, Research and practice in thrombosis and haemostasis.

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists

M. Kruip, S. Cannegieter, F. V. D. van der Meer, 2021, Blood.

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists

M. Kruip, S. Cannegieter, F. V. D. van der Meer, 2021, Thrombosis and Haemostasis.

Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.

H. Buller, M. Kappelhof, M. Nierman, 2017, The Netherlands journal of medicine.

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists

M. Kruip, M. Huisman, C. V. van Ommen, 2023, Thrombosis Research.

Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

A. Hoes, H. Koek, G. Geersing, 2023, Circulation.

Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.

N. Nurmohamed, L. Reeskamp, G. K. Hovingh, 2024, Atherosclerosis.